- Home
- UGI vs PRAX Comparison
UGI vs PRAX Comparison
Compare UGI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UGI | PRAX |
|---|---|---|
| Founded | 1940 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 8.6B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | UGI | PRAX |
|---|---|---|
| Price | $38.26 | $332.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 15 |
| Target Price | $44.00 | ★ $519.60 |
| AVG Volume (30 Days) | ★ 2.7M | 540.8K |
| Earning Date | 02-04-2026 | 02-19-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | ★ 6.31 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $7,340,000,000.00 | $7,463,000.00 |
| Revenue This Year | $8.88 | N/A |
| Revenue Next Year | $2.27 | $29,535.93 |
| P/E Ratio | $14.05 | ★ N/A |
| Revenue Growth | 3.10 | ★ 364.98 |
| 52 Week Low | $29.03 | $26.70 |
| 52 Week High | $41.34 | $328.60 |
Technical Indicators
Market Signals| Indicator | UGI | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 49.87 | 65.44 |
| Support Level | $36.93 | $302.00 |
| Resistance Level | $40.98 | $328.60 |
| Average True Range (ATR) | 1.05 | 16.96 |
| MACD | -0.23 | -0.12 |
| Stochastic Oscillator | 33.56 | 94.65 |
Price Performance
Historical ComparisonAbout UGI UGI Corporation
UGI Corp is an American holding company that, through its subsidiaries, is involved in the transport and marketing of energy and related services. Its segments include AmeriGas Propane, UGI International, Midstream & Marketing, and Utilities. The AmeriGas Propane segment consists of the propane distribution business. The UGI International segment consists of LPG distribution businesses. The Midstream & Marketing segment consists of energy-related businesses. The Utilities segment consists of the regulated natural gas and electric distribution. The company derives a majority of its revenue from the UGI International segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.